ENETS Abstract Search

Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience

#3070

Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres

Aim(s): To evaluate the activity and safety of Avelumab in MCC

Materials and methods: We performed a retrospective analysis of all MCC patients (pts) treated with Avelumab, 600 mg median dose once every 14 days, between March 2018 and November 2019

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,

Keywords: mcc, avelumab, activity, safety,

To read the full abstract, please log into your ENETS Member account.